Treatment of Subcutaneous Cellulitis with Normal WBC Count and No MRSA Risk Factors
For nonpurulent cellulitis in a patient with a normal white cell count (~9,000/µL) and no MRSA risk factors, treat with a β-lactam antibiotic targeting β-hemolytic streptococci, such as cephalexin 500 mg orally four times daily or amoxicillin 500 mg orally three times daily for 5-10 days. 1
Clinical Reasoning
The normal white cell count and absence of MRSA risk factors indicate this is likely uncomplicated, nonpurulent cellulitis. The key distinction here is nonpurulent (no purulent drainage, exudate, or associated abscess), which fundamentally changes the treatment approach 1.
Why β-Lactam Monotherapy is Appropriate
- β-hemolytic streptococci are the predominant pathogens in nonpurulent cellulitis, not Staphylococcus aureus 1
- The IDSA guidelines explicitly state that for nonpurulent cellulitis, empirical therapy for β-hemolytic streptococci is recommended, while the role of CA-MRSA is unknown 1
- MRSA coverage is NOT routinely needed unless the patient fails to respond to β-lactam therapy or has systemic toxicity 1
- A landmark 2017 randomized trial demonstrated that adding trimethoprim-sulfamethoxazole (MRSA coverage) to cephalexin provided no additional benefit over cephalexin alone for uncomplicated cellulitis 2
Specific Antibiotic Options
First-line oral β-lactams (choose one): 1
- Cephalexin 500 mg orally four times daily
- Dicloxacillin 500 mg orally four times daily
- Amoxicillin 500 mg orally three times daily
- Penicillin VK (for pure streptococcal coverage)
Duration: 5-10 days, with 5 days being sufficient if clinical improvement occurs by day 5 1
When to Consider MRSA Coverage
Add MRSA-active therapy ONLY if: 1
- Patient fails to respond to β-lactam therapy after 48-72 hours
- Systemic toxicity is present (high fever, hypotension, confusion)
- Purulent drainage develops
- Penetrating trauma or IV drug use is involved
- Patient has documented MRSA colonization or prior MRSA infection
If MRSA coverage becomes necessary, options include: 1
- Clindamycin 300-450 mg orally three times daily (covers both streptococci and MRSA)
- TMP-SMX 1-2 double-strength tablets orally twice daily PLUS a β-lactam (amoxicillin)
- Doxycycline 100 mg orally twice daily PLUS a β-lactam
Common Pitfalls to Avoid
Do NOT routinely add MRSA coverage for typical nonpurulent cellulitis. Despite the rise of community-acquired MRSA, prospective studies show that β-lactam therapy (cefazolin/oxacillin) was successful in 96% of cellulitis cases, demonstrating MRSA is an uncommon cause of typical cellulitis 1, 3, 4
Do NOT use TMP-SMX or doxycycline as monotherapy for nonpurulent cellulitis, as their activity against β-hemolytic streptococci is not well-defined 1
Do NOT prescribe rifampin as monotherapy or adjunctive therapy for cellulitis 1